Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomics
Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at JPMorgan Chase & Co. from $160.00 to $200.00. They now have an "overweight" rating on the stock.
Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer [Yahoo! Finance]
Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer
Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment [Yahoo! Finance]